NeuroPace, Inc.

NASDAQ:NPCE

Medical - Devices

Healthcare
$8.22 +0.30%

+$0.05 today

Market cap
$283.19M
Beta
1.88
P/E (TTM)
-23.8
EPS (TTM)
-$0.64
52W Low $7.56High $19.60

Volume 0.31M

Average 0.18M

NPCE Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

NeuroPace, Inc.NASDAQ: NPCE

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital declines year over year

Q1 FY2026 change in working capital of $2.39M (cash outflow) fell 45.4% year over year, ahead of the -71.7% change in trailing-twelve-month change in working capital. Sequentially, it rose 3690.5% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.

Context

  • Change in working capital amounted to 4.0% of revenue in FY2025, down 2.8 pp from a year earlier.
  • Change in working capital grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -45.4% holds above the trailing-twelve-month pace of -71.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.39M+3690.5% QoQ
Last fiscal yearDec 2025
-$4.01M-26.4% YoY
LTMMar 2026
-$2.03M-71.7% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.4%——
1 year-26.4%——
3-year CAGR-5.7%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(4.01M) USD
Year-over-year change
+26.4%

Change in Working Capital vs competitors

How NPCE compares with its peers on the latest reported figures

  • NPCE's LTM Mar 2026 change in working capital of $2.03M is the largest of the 2 companies compared; the peer median is $451K.
  • Its year-over-year change of -71.7% is the lowest of 2, against a peer median of +162.6%.
  • Change in working capital amounts to 2.0% of revenue for NPCE, versus a peer median of 0.8%.
NPCE Competitors Peer median
Change in Working Capital for NPCE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NPCENeuroPace, Inc.LTM Mar 2026$2.03M -71.7%-5.7%2.0%
CVRXCVRx, Inc.LTM Mar 2026$451K +162.6%—0.8%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding NPCE) $451K+162.6%—0.8%

Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.08M)(47.08M)(32.96M)(27.14M)(21.47M)
Depreciation & Amortization296K2.99M1.61M1.77M1.95M
Deferred Income Tax5.48M0000
Stock-Based Compensation4.29M8.35M9.56M10.28M11.09M
Change in Working Capital368K(4.79M)(2.48M)(5.45M)(4.01M)
Accounts Receivables1.3M(391K)(4.85M)(537K)(1.83M)
Inventory(1.16M)(2.13M)(1.7M)251K(3.67M)
Accounts Payables479K647K240K671K(730K)
Other Working Capital(259K)(2.91M)3.82M(5.84M)2.22M
Other Non-Cash Items1.07M3.67M4.58M2.59M1.43M
Operating Cash Flow(24.58M)(36.87M)(19.7M)(17.95M)(11.01M)
Capital Expenditures(384K)(603K)(173K)(306K)(332K)
Acquisitions (Net)00000
Purchases of Investments(85.01M)0000
Sales of Investments024.4M23.2M9.3M0
Other Investing Activities00000
Investing Cash Flow(85.4M)23.8M23.03M8.99M(332K)
Debt Repayment(4.09M)000(2.07M)
Common Stock Issued109.09M07.89M3.28M71.76M
Common Stock Repurchased0000(49.55M)
Dividends Paid00000
Other Financing Activities(2.47M)490K239K1.05M(543K)
Financing Cash Flow102.53M490K8.13M4.33M19.6M
Effect of Forex Changes00000
Net Change in Cash(7.45M)(12.58M)11.45M(4.63M)8.26M
Free Cash Flow(24.96M)(37.47M)(19.87M)(18.26M)(11.34M)

NeuroPace, Inc.

NASDAQ:NPCE

Intrinsic Alpha fair value

Locked

Current Price

$8.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.